| International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma WD Travis, E Brambilla, M Noguchi, AG Nicholson, KR Geisinger, ... Journal of thoracic oncology 6 (2), 244-285, 2011 | 5913 | 2011 |
| MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling JA Engelman, K Zejnullahu, T Mitsudomi, Y Song, C Hyland, JO Park, ... science 316 (5827), 1039-1043, 2007 | 5421 | 2007 |
| Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label … T Mitsudomi, S Morita, Y Yatabe, S Negoro, I Okamoto, J Tsurutani, T Seto, ... The lancet oncology 11 (2), 121-128, 2010 | 4877 | 2010 |
| Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival J Takamizawa, H Konishi, K Yanagisawa, S Tomida, H Osada, H Endoh, ... Cancer research 64 (11), 3753-3756, 2004 | 3360 | 2004 |
| Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications T Kosaka, Y Yatabe, H Endoh, H Kuwano, T Takahashi, T Mitsudomi Cancer research 64 (24), 8919-8923, 2004 | 1587 | 2004 |
| EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors YL Choi, M Soda, Y Yamashita, T Ueno, J Takashima, T Nakajima, ... New England Journal of Medicine 363 (18), 1734-1739, 2010 | 1441 | 2010 |
| Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non–small-cell lung cancer with postoperative … T Mitsudomi, T Kosaka, H Endoh, Y Horio, T Hida, S Mori, S Hatooka, ... Journal of Clinical Oncology 23 (11), 2513-2520, 2005 | 1183 | 2005 |
| Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer PM Forde, J Spicer, S Lu, M Provencio, T Mitsudomi, MM Awad, E Felip, ... New England Journal of Medicine 386 (21), 1973-1985, 2022 | 1164 | 2022 |
| Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas T Hida, Y Yatabe, H Achiwa, H Muramatsu, K Kozaki, S Nakamura, ... Cancer research 58 (17), 3761-3764, 1998 | 1154 | 1998 |
| Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial T Hida, H Nokihara, M Kondo, YH Kim, K Azuma, T Seto, Y Takiguchi, ... The Lancet 390 (10089), 29-39, 2017 | 897 | 2017 |
| Reduced expression of Dicer associated with poor prognosis in lung cancer patients Y Karube, H Tanaka, H Osada, S Tomida, Y Tatematsu, K Yanagisawa, ... Cancer science 96 (2), 111-115, 2005 | 828 | 2005 |
| Analysis of epidermal growth factor receptor gene mutation in patients with non–small cell lung cancer and acquired resistance to gefitinib T Kosaka, Y Yatabe, H Endoh, K Yoshida, T Hida, M Tsuboi, H Tada, ... Clinical Cancer Research 12 (19), 5764-5769, 2006 | 753 | 2006 |
| Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor–activating mutations S Yano, W Wang, QI Li, K Matsumoto, H Sakurama, T Nakamura, H Ogino, ... Cancer research 68 (22), 9479-9487, 2008 | 745 | 2008 |
| Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer T Mitsudomi, Y Yatabe Cancer science 98 (12), 1817-1824, 2007 | 722 | 2007 |
| Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non … H Saji, M Okada, M Tsuboi, R Nakajima, K Suzuki, K Aokage, T Aoki, ... The Lancet 399 (10335), 1607-1617, 2022 | 717 | 2022 |
| Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer T Mitsudomi, Y Yatabe The FEBS journal 277 (2), 301-308, 2010 | 694 | 2010 |
| Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. I Chiba, T Takahashi, MM Nau, D D'Amico, DT Curiel, T Mitsudomi, ... Oncogene 5 (10), 1603-1610, 1990 | 676 | 1990 |
| Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study G Goss, CM Tsai, FA Shepherd, L Bazhenova, JS Lee, GC Chang, ... The lancet oncology 17 (12), 1643-1652, 2016 | 669 | 2016 |
| A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology … K Suzuki, T Koike, T Asakawa, M Kusumoto, H Asamura, K Nagai, H Tada, ... Journal of thoracic oncology 6 (4), 751-756, 2011 | 602 | 2011 |
| p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. T Mitsudomi, SM Steinberg, MM Nau, D Carbone, D D'Amico, S Bodner, ... Oncogene 7 (1), 171-180, 1992 | 592 | 1992 |
Y. YATABEVerified email at ncc.go.jp
